257 related articles for article (PubMed ID: 19373942)
1. The efficacy of combined treatment with cetuximab (erbitux) and radiation therapy in patients with head and neck cancer.
Koukourakis G; Kouloulias V; Koukourakis M; Kouvaris J; Zacharias G; Gouliamos A
J BUON; 2009; 14(1):19-25. PubMed ID: 19373942
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab combined with radiotherapy: an alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck?
Bernier J; Schneider D
Eur J Cancer; 2007 Jan; 43(1):35-45. PubMed ID: 17098420
[TBL] [Abstract][Full Text] [Related]
3. Cetuximab in the management of locoregionally advanced head and neck cancer: expanding the treatment options?
Bourhis J; Lefebvre JL; Vermorken JB
Eur J Cancer; 2010 Jul; 46(11):1979-89. PubMed ID: 20561781
[TBL] [Abstract][Full Text] [Related]
4. EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines.
Jedlinski A; Ansell A; Johansson AC; Roberg K
J Oral Pathol Med; 2013 Jan; 42(1):26-36. PubMed ID: 22643066
[TBL] [Abstract][Full Text] [Related]
5. EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.
Sundvall M; Karrila A; Nordberg J; Grénman R; Elenius K
Expert Opin Emerg Drugs; 2010 Jun; 15(2):185-201. PubMed ID: 20415599
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor directed therapy in head and neck cancer.
Choong NW; Cohen EE
Crit Rev Oncol Hematol; 2006 Jan; 57(1):25-43. PubMed ID: 16207530
[TBL] [Abstract][Full Text] [Related]
7. Head and neck cancer: integrating anti-EGFR treatment with standard therapy.
Kies MS
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S52-9. PubMed ID: 19780246
[TBL] [Abstract][Full Text] [Related]
8. A multidisciplinary approach to squamous cell carcinomas of the head and neck: an update.
Bernier J
Curr Opin Oncol; 2008 May; 20(3):249-55. PubMed ID: 18391622
[TBL] [Abstract][Full Text] [Related]
9. Radiation combined with EGFR signal inhibitors: head and neck cancer focus.
Harari PM; Huang S
Semin Radiat Oncol; 2006 Jan; 16(1):38-44. PubMed ID: 16378905
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab in the treatment of head and neck cancer.
Bernier J
Expert Rev Anticancer Ther; 2006 Nov; 6(11):1539-52. PubMed ID: 17134359
[TBL] [Abstract][Full Text] [Related]
11. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.
Curran D; Giralt J; Harari PM; Ang KK; Cohen RB; Kies MS; Jassem J; Baselga J; Rowinsky EK; Amellal N; Comte S; Bonner JA
J Clin Oncol; 2007 Jun; 25(16):2191-7. PubMed ID: 17538164
[TBL] [Abstract][Full Text] [Related]
12. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis.
Huang SM; Harari PM
Clin Cancer Res; 2000 Jun; 6(6):2166-74. PubMed ID: 10873065
[TBL] [Abstract][Full Text] [Related]
13. Treatment of HNSCC cell lines with the EGFR-specific inhibitor cetuximab (Erbitux) results in paradox phosphorylation of tyrosine 1173 in the receptor.
Mandic R; Rodgarkia-Dara CJ; Zhu L; Folz BJ; Bette M; Weihe E; Neubauer A; Werner JA
FEBS Lett; 2006 Sep; 580(20):4793-800. PubMed ID: 16904111
[TBL] [Abstract][Full Text] [Related]
14. Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck.
Bernier J
Nat Clin Pract Oncol; 2008 Dec; 5(12):705-13. PubMed ID: 18825142
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab in squamous cell carcinoma of the head and neck.
Hitt R; Martín P; Hidalgo M
Future Oncol; 2006 Aug; 2(4):449-57. PubMed ID: 16922611
[TBL] [Abstract][Full Text] [Related]
16. Emerging role of EGFR-targeted therapies and radiation in head and neck cancer.
Song J; Chen C; Raben D
Oncology (Williston Park); 2004 Dec; 18(14):1757-67; discussion 1767, 1771-2, 1777. PubMed ID: 15700625
[TBL] [Abstract][Full Text] [Related]
17. Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.
Rivera F; García-Castaño A; Vega N; Vega-Villegas ME; Gutiérrez-Sanz L
Expert Rev Anticancer Ther; 2009 Oct; 9(10):1421-8. PubMed ID: 19828002
[TBL] [Abstract][Full Text] [Related]
18. Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
Klinghammer K; Knödler M; Schmittel A; Budach V; Keilholz U; Tinhofer I
Clin Cancer Res; 2010 Jan; 16(1):304-10. PubMed ID: 20028750
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications.
Langer CJ
Cancer; 2008 Jun; 112(12):2635-45. PubMed ID: 18442098
[TBL] [Abstract][Full Text] [Related]
20. Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro.
Zhang N; Erjala K; Kulmala J; Qiu X; Sundvall M; Elenius K; Grénman R
Radiother Oncol; 2009 Sep; 92(3):388-92. PubMed ID: 19447510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]